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Flaxseed  as  well  as  its  oil component  possess  antitumor  activities  against  different  types  of cancer  and
have  been  used  by some  patients  as  complementary  and/or  alternative  medicine.  Linoorbitides  (LOBs)
are one  family  of  ﬂaxseed  compounds  that  has  implications  for  anticancer  and  antioxidant  activity.  The
cytotoxicity  of  [1-9-NC]-linusorb-B3  (LOB3),  [1-9-NC]-linusorb-B2  (LOB2),  [1-9-NC],[1-Rs,Ss-MetO]-
linusorb-B2  ([MetO]-LOB2)  and  [1-8-NC],[1-Rs,Ss-MetO]-linusorb-B1  ([MetO]-LOB1)  was  measured
against  human  breast  cancer  Sk-Br-3  and  MCF7  cell  lines  and  melanoma  A375  cell line.  Overall  cyto-
toxicity  is cell-type  speciﬁc.  It scales  as  the  hydrophobicity  and  concentration  of the  LOBs  with  theytotoxicity
reast cancer
elanoma
most  abundant  LOB3  being  the  most  cytotoxic.  Oral  administration  of LOB3  as a potential  therapeu-
tic  agent  might  not  be applicable  as  a much  too  high  and/or  frequent  dose  would  be  required  to  achieve
a  serum  concentration  of 400–500  g/mL  due  to  bioavailability  and  pharmacokinetic  factors.  However,
LOB3  may  be  suitable  for  topical  treatment  formulations  or as  a lead compound  in  developing  anticancer
LOB  derivatives.
© 2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC. Introduction
The nutraceutical effects of ﬂaxseed have attracted signiﬁcant
esearch attention in recent years, leading to the identiﬁcation
nd isolation of various families of bioactive compounds [1–4].
inoorbitides (LOBs) are a group of thermostable hydrophobic
yclopeptide compounds present in ﬂaxseed oil. It has been noticed
hat cyclic peptides occur widely in both plants and animals
nd they can be broadly classiﬁed into two groups, cyclopep-
ides and cyclotides [5]. Various types of cyclopeptide have been
solated from plants and showed important biological functions
uch as anticancer, antidiabetic, cardio-protective and immuno-
uppressive properties, making them an abundant resource for
uture development of therapeutic agents [6,7,8–13]. For example,
unﬂower trypsin inhibitor 1 (SFTI-1), a cyclopeptide containing
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214-7500/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
14-amino acids, has been used as the template to develop potent
inhibitors of matriptase, which is present on the surface of certain
types of cancer cells [14,15].
Many cancer patients seek treatments with complementary
and/or alternative medicine (CAM), especially when they have
developed drug resistance towards chemotherapies. According
to the 2007 Statistics on CAM Use in the United States, 23% of
American cancer patients use CAM [16]. The actual number is likely
to be higher as many cancer patients do not tell their physicians or
oncologists about CAM usage. Flaxseed as well as its oil component
have been observed to exhibit antitumor activities towards differ-
ent types of cancer [12,17–19], making ﬂaxseed a CAM candidate
for human cancer treatment. Flaxseed oil could even increase the
therapeutic efﬁcacy of trastuzumab against HER2-overexpressing
breast cancer [20]. In spite of being a family of bioactive compounds
in ﬂaxseed oil, previous studies on ﬂaxseed LOBs have mainly
focused on the immunosuppressive and antimalarial activities
of linoorbitide [1-9-NC]-linusorb-B3 (LOB3) and its analogues.
However, a recent study showed that LOBs increased the oxidative
stability of ﬂaxseed oil in their natural matrix and might possess
anti-oxidative activity in vivo [21], implying that LOBs might
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ossess anticancer activities. Furthermore, the calculated log P
logarithm of partition coefﬁcient) values for the LOBs are between
 and 5 (from ALOGPS, http://www.vcclab.org); making them
uitable for both oral and topical administrations according to
ipinski’s rule [22]. In the current study, we investigated whether
axseed LOBs could impose cytotoxic effect towards human breast
ancer and melanoma cells.
. Materials and methods
.1. Materials
All chemicals used in the current study were purchased from
igma–Aldrich Canada (Oakville, ON, Canada). The LOBs were a gift
rom Prairie Tide Chemicals (Saskatoon, SK Canada). Four linoor-
itides LOB3, LOB2, [MetO]-LOB2 and [MetO]-LOB1 (Fig. 1) were
sed in this study. The elution order on a C18 reversed stationary
ig. 1. Chemical structures of linoorbitide LOB3 (NC-[Ile-Leu-Val-Pro-Pro-Phe-Phe-L
MetO-Leu-Ile-Pro-Pro-Phe-Phe-Val-Ile]) and [MetO]-LOB1 (NC-[Met-Leu-Val-Phe-Pro- Reports 2 (2015) 1014–1018 1015
phase liquid chromatograph column is [MetO]-LOB2 < [MetO]-
LOB1 < LOB2 < LOB3 (Fig. 2). Of note is that both [MetO]-LOB2 and
[MetO]-LOB1 contain methionine sulfoxide in their ring, which
makes them less hydrophobic than their methionine contain-
ing counterparts [23]. Stock solutions of the LOBs were prepared
in dimethyl sulfoxide (DMSO). Human melanoma cell line A375
and breast cancer cell lines Sk-Br-3 and MCF7 were purchased
from the American Type Culture Collection (ATCC) (Manassas, VA,
USA). ATCC-formulated cell culture medium for each cell line was
purchased from Cedarlane Canada (Burlington, ON,  Canada). The
CytoTox 96® Non-Radioactive Cytotoxicity Assay was purchased
from the Promega Corporation (Madison, WI,  USA).
2.2. Cell cultureHuman melanoma cell line A375 and breast cancer cell lines
Sk-Br-3 and MCF7 were cultured in T-75 culture ﬂasks under ATCC-
recommended cell culture conditions at 5% CO2 and 37 ◦C in a
eu-Ile]), LOB2 (NC-[Met-Leu-Ile-Pro-Pro-Phe-Phe-Val-Ile]), [MetO]-LOB2 (NC-
Leu-Phe-Ile]).
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Fig. 2. Reversed phase HPLC chromatogram from a Chromolith® HighResolution RP-18e C-18 column (4.6 mm × 50 mm).  The column was eluted by a linear gradient of water
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on the experimental results on A375 and Sk-Br-3 cells. Interest-
ingly, [MetO]-LOB2 and [MetO]-LOB1 showed small cytoprotective
effects for the MCF7 cells instead of being cytotoxic.
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500 125 31.25 7.81 1.95nd  acetonitrile (50:50–20:80 in 1.8 min, to 10:90 in 0.1 min, to 50:50 in 0.1 min  an
hermo FormaTM Series II Water-Jacketed CO2 incubator (Thermo
isher Scientiﬁc, Waltham, MA,  USA). Cell culture media were
hanged every 2–3 d for each cell line.
.3. Cytotoxicity assay
The cytotoxicity of LOBs was assayed in three independent
xperiments with each experiment carried out in triplicate. Brieﬂy,
he cultured cells were plated in 96-well plates with 5000 cells/well
or cell line A375 and 10,000 cells/well for cell lines Sk-Br-3
nd MCF7. The plated cells were allowed to grow to 70–80%
onﬂuence before being treated with LOBs for 24 h and 48 h, respec-
ively. The administered concentrations for LOBs were 500 M,
25 M,  31.25 M,  7.85 M and 1.95 M for A375 cells, 400 g/mL,
00 g/mL, 100 g/mL, 50 g/mL and 25 g/mL for Sk-Br-3 cells,
nd 200 g/mL, 100 g/mL, 50 g/mL, 25 g/mL and 12.5 g/mL
or MCF7 cells. As molecular weights for all four LOBs are approx-
mately 1000 daltons, their concentrations were approximately
t 1 M ≈ 1 g/mL. Cells treated with DMSO (ﬁnal concentration
t 2%) were used as negative control. Cytotoxicity of the LOBs
as measured using the CytoTox96® Non-Radioactive Cytotoxicity
ssay.
.4. Interaction between LOBs and phospholipid bubbles
Micron-sized phospholipid bubbles were generated by adding
.5 mg  of 1,2-distearoyl-sn-glycero-3-phosphocholine into 15 mL
f H2O and vortexed (∼900 rpm) at room temperature for 30 s
sing a VWR  analogue vortex mixer. LOB solutions were prepared
y adding 1 mg  of LOBs to 50 L of 80% methanol. The interac-
ion between LOBs and phospholipid bubbles was investigated by
dding 10 L of each respective LOB solution into 100 L bubble
uspension, vortexed (∼900 rpm) at room temperature for 30 s, and
maged immediately under a microscope at 100× magniﬁcation.
. Results and discussion
Cytotoxicity of LOB3, LOB2, [MetO]-LOB2 and [MetO]-LOB1
gainst melanoma A375 cells were measured at 24 h and 48 h of
xposure time, respectively. At 24 h, no cytotoxicity was  observed
or any of the four LOBs. As the exposure was increased to 48 h,
OB3, [MetO]-LOB2 and [MetO]-LOB1 exhibited increased toxicity
f 56%, 32% and 26%, respectively, compared to the control at con-
entration of 500 M (Fig. 3). As LOB concentration decreased toquilibration for 1 min) with a ﬂow rate of 2 mL/min at 32 C.
125 M,  only LOB3 showed a marginal cytotoxicity of 10%. How-
ever, no cytotoxicity was observed for LOB2 at any concentration
(Fig. 3). Subsequently, the cytotoxicity of the four LOBs was mea-
sured against breast cancer Sk-Br-3 and MCF7 cells. As shown
in Fig. 4, the respective cytotoxicity of LOB3, LOB2, [MetO]-LOB2
and [MetO]-LOB1 was at 75%, 41%, 36% and 28% towards the Sk-
Br-3 cells after 24 h of exposure at 400 g/mL. [MetO]-LOB2 and
[MetO]-LOB1 only showed cytotoxicity at 400 g/mL; however,
both LOB3 and LOB2 exhibited a concentration-dependent cyto-
toxic response. As the concentration was reduced to 25 g/mL,
only 9% and 6% of cytotoxicity were remained for LOB3 and LOB2,
respectively. When the exposure time was  increased to 48 h, the
cytotoxicity of LOB3 was signiﬁcantly reduced to 45%, whereas
LOB2, [MetO]-LOB2 and [MetO]-LOB1 maintained their respective
cytotoxicity, at 400 g/mL. For MCF7 cells, the maximum concen-
tration of LOBs used for treatment was  200 g/mL. As illustrated
in Fig. 5, only LOB3 and LOB2 exhibited cytotoxicity at 18% and
19%, respectively, after 24 h of exposure and 7% and 8%, respec-
tively, after 48 h of exposure. This observation was  consistent with
the experiment on breast cancer Sk-Br-3 cells where it was seen
that cytotoxicity of both LOB3 and LOB2 was  reduced due to pro-
longed treatment. We  speculated that the cytotoxicity of LOB3 and
LOB2 would be much higher at concentration of 400 g/mL basedFig. 3. Cytotoxicity (mean ± standard deviation) of linoorbitide LOB3, LOB2, [MetO]-
LOB2 and [MetO]-LOB1 against human melanoma A375 cells at 48 h of exposure.
The data were obtained from three independent experiments with each experiment
carried out in triplicate.
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Fig. 4. Cytotoxicity (mean ± standard deviation) of linoorbitide LOB3, LOB2, [MetO]-
LOB2 and [MetO]-LOB1 against human breast cancer Sk-Br-3 cells at 24 h (A) and
48  h (B) of exposure. The data were obtained from three independent experiments
with each experiment carried out in triplicate.
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Fig. 5. Cytotoxicity (mean ± standard deviation) of linoorbitide LOB3, LOB2, [MetO]-
LOB2 and [MetO]-LOB1 against human breast cancer MCF7 cells at 24 h (A) and 48 h
(B)  of exposure. The data were obtained from three independent experiments with
each experiment carried out in triplicate.
Fig. 6. Images of the interactions between micron-sized phospholipid (1,2-distearoyl-sn-glycero-3-phosphocholine) bubbles and ﬂaxseed LOB3, LOB2, [MetO]-LOB2 and
[MetO]-LOB1 were taken under 100× magniﬁcation using a microscope attached to a Raman spectrophotometer at the Saskatchewan Structural Sciences Centre. The
phospholipid bubbles were imaged at 100 m × 100 m,  the interactions of the phospholipid bubbles with the LOBs were imaged at 50 m × 50 m, and the “zoom-in”
views  of phospholipid bubble interactions with LOB3 and LOB2 were imaged at 10 m × 10 m.
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In the current study, we showed that the cytotoxicity of LOBs
as highly cell-type speciﬁc and concentration dependent. Since
ancer cells normally retain high levels of reactive oxygen species
ROS), the anti-oxidative activity of LOBs might be important in
liciting their cytotoxic effects against cancer cells. Furthermore,
e hypothesized that the hydrophobicity of LOBs might play an
ssential role in their interaction with cell membranes and this
nteraction would be the ﬁrst step towards cytotoxicity. To test our
ypothesis, micron-sized phospholipid bubbles were generated to
imic  cell membranes for the study of their interaction with LOBs.
s shown in Fig. 6, the order of interacting activity for this model
ystem was [MetO]-LOB2 < [MetO]-LOB1 < LOB2 < LOB3, which was
he same as the hydrophobicity order of the LOBs determined by
PLC (Fig. 2). Continuous observation under a microscope at 100×
agniﬁcation showed that LOB3 attached to the phospholipid bub-
les, which in turn caused rapid aggregation and breakage of the
ubbles. LOB2 also caused quick phospholipid bubbles aggrega-
ion but broke them at a much slower rate. However, [MetO]-LOB2
xhibited only marginal activity in aggregating phospholipid bub-
les. Thus, hydrophobic interaction with cell membrane might be
nother contributing factor, other than the anti-oxidative function,
o the cytotoxic effects of LOBs against human cancer cells.
LOB3 possessed the highest in vitro antitumor activities against
ll three cancer cell lines at higher concentrations, which is
onsistent with the observation that LOB3 had higher immunosup-
ressive function than LOB2 [24]. Taking into consideration of the
ioavailability and pharmacokinetic factors, high and/or frequent
oses might be needed for oral administered LOB3 to reach a serum
oncentration of 400–500 g/mL, which is high and uncommon for
herapeutic drugs. Although it is impossible to predict how high the
ral dose of LOB3 should be without any pharmacokinetic studies,
uch too high dose requirement would deﬁnitely eliminate further
xploration on oral administration of LOB3. Intravenous infusion of
OB3 at 400–500 g/mL is likely to be toxic to human and might
ot be suitable for the treatment of human breast cancer and
elanoma. However, cream formulation of LOB3 might be appli-
able for topical usage against melanoma and perhaps other types
f skin cancer. In addition, we observed the cytotoxicity of [MetO]-
OB2 and [MetO]-LOB1 against melanoma A375 and breast cancer
k-Br-3 cells and LOB2 against breast cancer Sk-Br-3 and MCF7 cells
t high concentrations. They experience the same formulation con-
ern. In summary, pure LOBs, which are extracted from ﬂaxseed
il, are unlikely to have any potential as anticancer agents due to
he high concentration required for cytotoxicity. Synthetic deriva-
ives of LOBs with better pharmacological activity, bioavailability
nd pharmacokinetic proﬁle would likely be more applicable in
eveloping LOB-based cancer therapy regimens. Further studies
ncluding human breast cancer and melanoma xenograft models
re warranted in elucidating the anticancer function of ﬂaxseed
OBs and their derivatives.
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